Akebia Ther (NASDAQ: AKBA) — Perfil da empresa, notícias e dados financeiros
Akebia Therapeutics develops novel therapies for kidney disease, focusing on innovative treatments for patients in need.
Akebia Ther
Akebia Therapeutics (NASDAQ:AKBA) operates in the biopharmaceutical sector, focusing on the development and commercialization of therapeutics based on harnessing the potential of hypoxia-inducible factor (HIF) for patients with kidney disease and other metabolic disorders. Their primary project is the development of vadadustat, an oral therapy designed to treat anemia due to chronic kidney disease. Akebia's objectives revolve around addressing the unmet medical needs within the kidney disease community by providing innovative treatments aimed at improving patients' quality of life and clinical outcomes. The company is dedicated to advancing its project pipeline through rigorous research and development, aspiring to lead in the nephrology space by offering novel therapeutic solutions.
Resumo
Operações
Produtos e/ou serviços de Akebia Ther
- Vadadustat, an investigational oral therapy for anemia due to chronic kidney disease in adults.
- Auryxia (ferric citrate), FDA approved for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis and treating iron deficiency anemia in adults not on dialysis.
- Research and development in hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class for various therapeutic areas.
- Clinical trials for new therapeutic agents targeting chronic kidney disease and anemia.
- Partnerships for the development and commercialization of kidney disease and anemia treatments.
- Educational and support programs for clinicians and patients dealing with chronic kidney disease and anemia.
equipe executiva do Akebia Ther
- John P. ButlerCEO, President & Director
- Erik John OstrowskiChief Business Officer, Senior VP, CFO & Treasurer
- Steven Keith BurkeSenior VP and Chief Research & Development Officer
- Nicholas GrundSenior VP & Chief Commercial Officer
- Richard C. MalabreSenior VP & Chief Accounting Officer
- Justin McCueSenior VP & Chief Technology Officer
- Mercedes CarrascoSenior Director of Investor & Corporate Communications
- Carolyn M. RucciSenior VP, Chief Legal Officer & Secretary
- Meredith BowmanSenior VP & Chief People Officer
Principais indicadores financeiros
Resultados divulgados pela Akebia Ther, em USD.
- Cap. de mercado
- 183 mi
- Receita (TTM)
- 219,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -13.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 236,2 mi | 23,5 mi | -5,3 mi | |
| 160,2 mi | -50,5 mi | -69,4 mi | |
| 194,6 mi | -46,3 mi | -51,9 mi | |
| 292,5 mi | -80,8 mi | -94,2 mi |